The dot below represents the central spot, the epicenter of the company
The Mission of EpicentRx is Remission — remission of disease and remission of side effects.
The Golden Rule in medicine is “do no harm”. However, the all-too-common expression, “the cure is worse than the disease” suggests that harm is part and parcel of many treatments. EpicentRx has developed a new class of therapies that are intended to target a range of conditions with minimal toxicity and maximum activity.
Management Team
Behind the company’s mission is a group of exceptional people
Founded on a vision for better care
An exceptional leader and true visionary, Arnold Oronsky, Ph.D. founded EpicentRx to change the paradigm of how patients experience treatment. “Arnie” combined a deep understanding of medical research with a passion for improving the lives of patients and an exceptional talent for building teams focused on novel therapeutics. His legacy lives on in the team he assembled and the core mission of EpicentRx.
Chief Executive Officer
Dr. Tony Reid, Chief Executive Officer at EpicentRx, holds a PhD focused in Antiviral and Antitumor Activity from Stanford. Reid further pursued his MD at Stanford focusing on targeted viral vector for cancer therapy and histone deacetylase inhibitors. In addition to his role at EpicentRx, Reid continues his 13 years as a Professor of Medicine at the University of California San Diego Moores Cancer Center as a medical oncologist focused on early phase clinical research while simultaneously developing an adenoviral platform. Dr. Reid holds numerous national awards such as America’s Top Doctor (top 1%), 2008 to present, America’s Top Doctor for Cancer (top 1%), 2009 to present, and America’s Most Honored Professional (top 1%), 2016 to present.
Chief Financial Officer
Dr. Brinkhaus serves as EpicentRx Chief Financial Officer and has experience in strategic advice, corporate finance and capital raising for life science companies. He is CEO & Founder of Biotech Alliances International, Inc., a Silicon Valley-based life sciences investment bank. Previously, Dr. Brinkhaus was Managing Director of Palo Alto-based Woodside Capital Partners. He holds a Master’s degree and a Ph.D. in Economics.
Chief Neuroscience Collaborator
Dr Richard Gordon leads the Translational Neuroscience Laboratory at The University of Queensland and has a career track record of research in neuroinflammation. His research program aims to develop new therapeutic strategies for the treatment Parkinson’s disease and other neurodegenerative disorders, with a focus on targeting chronic immune and inflammasome activation which drives neurodegeneration. Dr Gordon’s research has contributed to groundbreaking advances in the field neuroinflammation, including most recently, the discovery inflammasome activation in PD as a key driver of synuclein pathology and disease progression. He also Dr Gordon is a board-certified Toxicologist with the American Board of Toxicology (ABT). He is also a Science Ambassador for the World Parkinson’s Coalition and has served on the Gene Technology Technical Advisory Committee (GTTAC) for the Department of Health for the Australian Federal Government.
Chief Development Officer
Dr. Bryan Oronsky serves as EpicentRx Chief Development Officer and combines firsthand clinical experience as a physician with 17 years of pharmaceutical development experience.
Vice President of Viral Therapy
Chris Larson completed an MD/PhD program at UT Southwestern in 2009 with a dissertation in molecular biophysics. Thereafter he completed a residency in Internal Medicine and a fellowship in Hematology/Oncology at UC San Diego where he worked in the lab of Dr. Tony Reid on oncolytic viruses (OVs). Chris was hired by EpicentRx in 2017 when the company acquired the OV technology.
At EpicentRx, his work focuses on the clinical translation of AdAPT-001 and the development of in-house manufacturing processes.
Vice President of Finance & Special Projects
Leads financial reporting, accounting, and related internal controls. Since joining in 2015, Mrs. Stirn has served various roles in clinical, corporate, and financial operations. Mrs. Stirn has over 15 years of experience in clinical research management, specializing in oncology and immunology. BA in Chemistry and a BS in Physiological Sciences from the University of Arizona and earned a MBA in Accounting from National University.
Sr. Director of Operations & Corporate Development
10 years experience in Clinical Program Development and Life Science Business Strategies. Responsible for Global Operations, working directly with the Executive Team and helps to drive business development by prioritizing opportunities, conducting diligence, and transacting business and collaboration opportunities. Mr. Caroen is a co-author on over 40 peer reviewed scientific publications and co-inventor on 3 pending patents.
General Counsel
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque vehicula bibendum neque ut pharetra. Vivamus vel pharetra urna. Nullam viverra sit amet sapien dapibus viverra. Aliquam erat volutpat. Integer diam ipsum, vehicula ac ante ac, ornare eleifend dui. Etiam molestie magna ipsum, dapibus consequat sapien rhoncus eget. Donec vitae augue vitae nibh accumsan aliquam. Sed tempus laoreet vestibulum. In vitae aliquam diam. Etiam nisi purus, egestas in finibus eget, lobortis at elit. Aliquam porttitor dictum risus, quis ornare magna finibus at. Proin sed maximus sem. In vulputate velit nisl, non fermentum ante euismod id.
Human Resources
I’ve been an HR professional for more than 30 years. About half of that experience was in large corporations, some with more than 2500 employees and some with only four employees. My most recent corporate experience was Vice-President of Human Resources and Administration for Toshiba. During this time, I also spent about 12 years providing as needed human resources consulting services to companies across a wide range of industries. I have a B.S. in Business Administration from California State University, Pomona and an MBA from the University of Phoenix. In 2001, I earned a certificate in Life Coaching from the Hudson Institute of Santa Barbara. Currently, in addition to teaching at up to six different campuses and running my private consulting practice, I speak to groups on various HR and employment related topics such as employee retention and avoiding sexual harassment and litigation.
VP, Quality
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque vehicula bibendum neque ut pharetra. Vivamus vel pharetra urna. Nullam viverra sit amet sapien dapibus viverra. Aliquam erat volutpat. Integer diam ipsum, vehicula ac ante ac, ornare eleifend dui. Etiam molestie magna ipsum, dapibus consequat sapien rhoncus eget. Donec vitae augue vitae nibh accumsan aliquam. Sed tempus laoreet vestibulum. In vitae aliquam diam. Etiam nisi purus, egestas in finibus eget, lobortis at elit. Aliquam porttitor dictum risus, quis ornare magna finibus at. Proin sed maximus sem. In vulputate velit nisl, non fermentum ante euismod id.
Associate Professor of Radiation Oncology, Emerita, Stanford University
Stanford Hospital and Clinics, Lucile Packard Children’s Hospital
Chair of the Department of Radiation Oncology, University of Michigan
Isadore Lampe Professor of Radiation Oncology
Kraft Family Professor of Medicine, Medicine, Harvard Medical School
Physician, Oncology, Brigham And Women’s Hospital
Associate Professor of Radiation Oncology, Emerita, Stanford University
Stanford Hospital and Clinics, Lucile Packard Children’s Hospital
Chair of the Department of Radiation Oncology, University of Michigan
Isadore Lampe Professor of Radiation Oncology
Kraft Family Professor of Medicine, Medicine, Harvard Medical School
Physician, Oncology, Brigham And Women’s Hospital
Phase 3
Study: REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma
Conditions: Small Cell Lung Cancer
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin
Status: Active/Enrolling
Partnerships: SciClone Pharmaceuticals
Phase 2
Study: A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer (ROCKET)
Conditions: Metastatic Colorectal Cancer (mCRC)
Interventions: Drug: RRx-001 (investigational drug); Drug: Irinotecan; Drug: Regorafenib (comparator)
ClinicalTrials.gov Identifier: NCT02096354
Status: Completed/ Not Enrolling
Publications: [click to view]
Phase 2b
Study: Efficacy Study of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers (KEVLARx)
Conditions: Severe Oral Mucositis (SOM) in Head & Neck Cancers (HNC)
Interventions: Drug: RRx-001 (investigational drug); Drug: Cisplatin; Radiation: IMRT
ClinicalTrials.gov Identifier: NCT03515538
Status: In Start-up (not enrolling)
Publications: [click to view]
Phase 1
Study: A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab (PRIMETIME), completed. Phase 2 study in recurrent Head & Neck Cancer (in planning)
Conditions: Solid Tumors
Interventions: Drug: RRx-001 (investigational drug); Drug: Nivolumab (Phase 2 CPI, TBD)
ClinicalTrials.gov Identifier: NCT02518958 (completed study)
Status: In Start-up (not enrolling); (Phase 2 in planning)
Publications: [click to view]
Preclinical
Study: RRx-001 for reduction of endometrial lesions and associated pain
Conditions: Endometriosis
Interventions: Drug: RRx-001 (investigational drug)
ClinicalTrials.gov Identifier: NCT02518958
Status: Preclinical studies ongoing
Preclinical
Study: RRx-001 for prevention and treatment of neurodegenerative diseases
Conditions: Parkinson’s, ALS/MND, Alzheimer’s, & others
Interventions: Drug: RRx-001 (investigational drug)
ClinicalTrials.gov Identifier: NCT02518958
Status: Preclinical studies ongoing
Grant Awards:
Phase 1/2
Study: (planning)
Conditions: Solid Tumors
Interventions: Drug: AdAPT-001 (investigational drug)
Phase 1/2
Study: A Phase 1/2, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors
Conditions: Solid Tumors
Interventions: Drug: AdAPT-001 (investigational drug); Drug: Immune Checkpoint Inhibitor(s)
ClinicalTrials.gov Identifier: NCT04673942
Status: Enrolling